| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/04/2004 | EP1385542A2 Treatment and prevention of ebv infection and ebv-associated disorders |
| 02/04/2004 | EP1385541A1 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| 02/04/2004 | EP1385538A2 Chimeric vaccines |
| 02/04/2004 | EP1385533A1 Module of pd-1 interactions with its ligands |
| 02/04/2004 | EP1385479A1 Liposome composition for improved intracellular delivery of a therapeutic agent |
| 02/04/2004 | EP1385475A2 Immunity adjuvant containing a complexed metal cation and vaccine containing same |
| 02/04/2004 | EP1385452A1 Ophthalmic drug delivery device |
| 02/04/2004 | EP0789766B1 Chimeric papillomavirus-like particles |
| 02/04/2004 | EP0745386B1 Anti-aids secretory recombinant bcg vaccine |
| 02/04/2004 | EP0642507B1 Transition state analogues of cocaine, their use for producing catalytic antibodies against cocaine and use of the same in diagnosis and therapy |
| 02/04/2004 | CN1473166A Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 02/04/2004 | CN1473052A PSGL-1 regulator |
| 02/04/2004 | CN1473051A Use of immidazoquinolinamines as adjuvants in DNA vaccination |
| 02/04/2004 | CN1473050A Use of long pentraxin PTX3 for treatment of diseases caused by altered activation of growth factor FGF-2 |
| 02/04/2004 | CN1472321A Chemosynthesized SARS virus S gene segement, its expression and application |
| 02/04/2004 | CN1472315A Expression of larynogotracheitis or epiornitic virus gene recombined varicella virus and its use |
| 02/04/2004 | CN1472314A Immunity expression of AIDS virus O and its use |
| 02/04/2004 | CN1471975A Immune adjusting agent |
| 02/04/2004 | CN1471974A Anti-inflammatory agent |
| 02/04/2004 | CN1471973A Notoginseng saponine immunological component and vaccin preparation containing it |
| 02/04/2004 | CN1136918C Vaccines |
| 02/04/2004 | CN1136917C TB vaccine heat reversal protein 65 and multiepi-position HER-2 Antigen fusion protein recombinat protein vaccine |
| 02/03/2004 | US6686454 Antibodies to specific regions of cyclosporine related compounds |
| 02/03/2004 | US6686339 Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| 02/03/2004 | US6686191 Low level of anticomplement activity; contacting with trialkylphosphate and detergent then incubating |
| 02/03/2004 | US6686190 Methods for enhancing the production of viral vaccines in cell culture |
| 02/03/2004 | US6686179 Polypeptide for use in the treatment of thrombosis, cancer, inflammation, autoimmune, and bone disorders |
| 02/03/2004 | US6686153 PRV-1 gene and the use thereof |
| 02/03/2004 | US6685950 Methods of treating viral infections |
| 02/03/2004 | US6685948 Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines |
| 02/03/2004 | US6685947 Derived from canine distemper virus |
| 02/03/2004 | US6685946 Cold-adapted equine influenza viruses |
| 02/03/2004 | US6685945 Cloned Leptospira outer membrane protein |
| 02/03/2004 | US6685944 Modification of immunogenic epitopes of the hepatitis c virus core protein to elicit an enhanced immune response |
| 02/03/2004 | US6685943 Fibronectin binding protein compositions and methods of use |
| 02/03/2004 | US6685941 Immuosuppressant |
| 02/03/2004 | US6685940 Protein formulation |
| 02/03/2004 | US6685936 Administering lymphocytes |
| 02/03/2004 | US6685935 Vectors for the diagnosis and treatment of solid tumors including melanoma |
| 02/03/2004 | US6685911 Sensitization process for antigen-presenting cells and means for implementing the process |
| 02/03/2004 | CA2234151C Urogenital carcinoma tlp complex peptides and antibodies thereof |
| 02/03/2004 | CA2025597C Vaccine against lyme disease |
| 02/03/2004 | CA1341450C Methods and compositions for the preparation of treponema pallidum antigens, including purified antigens and dna sequences coding therefor |
| 01/29/2004 | WO2004009802A2 gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS |
| 01/29/2004 | WO2004009785A2 IgG Fc/HIV-gp120/C3d FUSION PROTEIN |
| 01/29/2004 | WO2004009776A2 TREATMENT OF TNFα RELATED DISORDERS |
| 01/29/2004 | WO2004009759A2 Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections |
| 01/29/2004 | WO2004009632A2 Method for the production of an immunostimulating mucin (muc1) |
| 01/29/2004 | WO2004009621A2 Polypeptides of nontypeable haemophilus influenzae |
| 01/29/2004 | WO2004009618A2 Recombinant production of mixtures of antibodies |
| 01/29/2004 | WO2004009124A2 Ghrelin-carrier conjugates |
| 01/29/2004 | WO2004009116A2 Hapten-carrier conjugates comprising virus like particles and uses thereof |
| 01/29/2004 | WO2004009089A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 01/29/2004 | WO2004009032A2 Method and composition for treating and preventing hepatitis b infection and symptoms thereof |
| 01/29/2004 | WO2004009029A2 Compositions and methods for treating and preventing infection |
| 01/29/2004 | WO2004009021A2 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/29/2004 | WO2003085098A3 Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti |
| 01/29/2004 | WO2003080654B1 Helicobacter flagellar, motility polypeptides |
| 01/29/2004 | WO2003078640A8 Recombinant drug-sensitive vaccinia virus as smallpox vaccine |
| 01/29/2004 | WO2003072018A3 Ricin vaccine and methods of making and using thereof |
| 01/29/2004 | WO2003054157A3 Dna encoding novel cyclic gmp dependent protein kinases from two protozoal sources for use as chemotherapeutic targets for antiprotozoal agents |
| 01/29/2004 | WO2003050241A3 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 01/29/2004 | WO2003048775A3 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 01/29/2004 | WO2003048184A3 Flavivirus ns1 subunit vaccine |
| 01/29/2004 | WO2003041650A3 Modulation of lir function to treat rheumatoid arthritis |
| 01/29/2004 | WO2003038113A3 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 01/29/2004 | WO2003017944A3 Gpi-anchored cytokines |
| 01/29/2004 | WO2003009803A3 Method of improving cognitive function |
| 01/29/2004 | WO2003000199A3 Ilt3 and ilt4-related compositions and methods |
| 01/29/2004 | WO2002099060A3 Dgks as modifiers of the p53 pathway and methods of use |
| 01/29/2004 | US20040019919 Calsyntenin-1-3 proteins, predominantly expressed in the nervous system , useful for the screening and for the preparation of a medicament for the treatment of nervous system disorders, most preferably brain |
| 01/29/2004 | US20040019917 NEOKINE protein and nucleic acid molecules and uses therefor |
| 01/29/2004 | US20040019915 Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
| 01/29/2004 | US20040019195 Foreign nucleic acid molecule encoding multiple costimulatory molecules, such as B7-1 or B7-2 (antigents), intercellular adhesion molecules and leukocyte function associated antigen-3 |
| 01/29/2004 | US20040019194 Ixodes salivary anticomplement protein |
| 01/29/2004 | US20040019190 Thrombopoietin mimetics |
| 01/29/2004 | US20040018980 Novel FIZZ proteins |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018639 Using extract from mammal thymus glands; analyzing precipitation patterns |
| 01/29/2004 | US20040018605 Anticancer agents; autoimmune diseases; central nervous system disorders; polymerase chain reactions |
| 01/29/2004 | US20040018571 PSCA: prostate stem cell antigen and uses thereof |
| 01/29/2004 | US20040018569 Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection |
| 01/29/2004 | US20040018555 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 01/29/2004 | US20040018525 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| 01/29/2004 | US20040018516 Ixodes scapularis tissue factor pathway inhibitor |
| 01/29/2004 | US20040018514 Nucleotide sequence derived from Listeria inocua |
| 01/29/2004 | US20040018508 Surrogate antibodies and methods of preparation and use thereof |
| 01/29/2004 | US20040018215 Methods for the in vitro culture of sporozoea sp. and uses thereof |
| 01/29/2004 | US20040018211 EIA vaccine and diagnostic |
| 01/29/2004 | US20040018209 Abundant extracellular products and methods for their production and use |
| 01/29/2004 | US20040018207 Preventive and therapeutic AIDS vaccines |
| 01/29/2004 | US20040018206 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens |
| 01/29/2004 | US20040018205 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof |
| 01/29/2004 | US20040018204 Compositions and methods for WT1 specific immunotherapy |
| 01/29/2004 | US20040018200 >/= 15 mg/ml of an antibody, or a fragment that immunospecifically binds to a respiratory syncytial virus antigen and histidine in an aqueous carrier |
| 01/29/2004 | US20040018199 Compositions and methods of use for an ephrin receptor |
| 01/29/2004 | US20040018198 Antibodies against carbonic anydrase IX (CA IX) tumor antigen |
| 01/29/2004 | US20040018196 Proteins and nucleic acids encoding same |
| 01/29/2004 | US20040018194 Administering proteins that bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement |
| 01/29/2004 | US20040018193 Rapid-acting broad spectrum protection against biological threat agents |